65 related articles for article (PubMed ID: 12368171)
1. Inhibition of fluid phase and clot-bound thrombin by the thrombin exosite I ligand LU 58463: comparison with heparin and hirudin.
Filippucci E; Agnelli G; Leone M; Nenci GG
Haematologica; 2002 Oct; 87(10):1116-7. PubMed ID: 12368171
[No Abstract] [Full Text] [Related]
2. The effects of exosite occupancy on the substrate specificity of thrombin.
Ng NM; Quinsey NS; Matthews AY; Kaiserman D; Wijeyewickrema LC; Bird PI; Thompson PE; Pike RN
Arch Biochem Biophys; 2009 Sep; 489(1-2):48-54. PubMed ID: 19638274
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-hirudin complex stability: a comparison with the thrombin-antithrombin III complex.
Römisch J; Pâques EP
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):643-6. PubMed ID: 1782334
[TBL] [Abstract][Full Text] [Related]
4. Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors.
Su Z; Vinogradova A; Koutychenko A; Tolkatchev D; Ni F
Protein Eng Des Sel; 2004 Aug; 17(8):647-57. PubMed ID: 15358856
[TBL] [Abstract][Full Text] [Related]
5. Binding of exosite ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II.
Verhamme IM; Olson ST; Tollefsen DM; Bock PE
J Biol Chem; 2002 Mar; 277(9):6788-98. PubMed ID: 11724802
[TBL] [Abstract][Full Text] [Related]
6. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Xu Y; Wu W; Wang L; Chintala M; Plump AS; Ogletree ML; Chen Z
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):332-8. PubMed ID: 23348428
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma.
Gast A; Tschopp TB; Schmid G; Hilpert K; Ackermann J
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):879-87. PubMed ID: 7893925
[TBL] [Abstract][Full Text] [Related]
8. [Inducing conformational changes in thrombin by ligands as a way of regulating its activity].
Gershkovich AA
Biokhimiia; 1996 Jul; 61(7):1139-51. PubMed ID: 9035728
[TBL] [Abstract][Full Text] [Related]
9. Anophelin: kinetics and mechanism of thrombin inhibition.
Francischetti IM; Valenzuela JG; Ribeiro JM
Biochemistry; 1999 Dec; 38(50):16678-85. PubMed ID: 10600131
[TBL] [Abstract][Full Text] [Related]
10. Ligand binding to anion-binding exosites regulates conformational properties of thrombin.
Malovichko MV; Sabo TM; Maurer MC
J Biol Chem; 2013 Mar; 288(12):8667-8678. PubMed ID: 23378535
[TBL] [Abstract][Full Text] [Related]
11. The role of Glu(192) in the allosteric control of the S(2)' and S(3)' subsites of thrombin.
Marque PE; Spuntarelli R; Juliano L; Aiach M; Le Bonniec BF
J Biol Chem; 2000 Jan; 275(2):809-16. PubMed ID: 10625611
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of recombinant hirudin.
Nowak G
Semin Thromb Hemost; 2002 Oct; 28(5):415-24. PubMed ID: 12420236
[TBL] [Abstract][Full Text] [Related]
13. Conformational changes in thrombin when complexed by serpins.
Fredenburgh JC; Stafford AR; Weitz JI
J Biol Chem; 2001 Nov; 276(48):44828-34. PubMed ID: 11584020
[TBL] [Abstract][Full Text] [Related]
14. The NMR solution structure of recombinant RGD-hirudin.
Song X; Mo W; Liu X; Zhu L; Yan X; Song H; Dai L
Biochem Biophys Res Commun; 2007 Aug; 360(1):103-8. PubMed ID: 17585879
[TBL] [Abstract][Full Text] [Related]
15. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
Thromb Haemost; 2009 May; 101(5):867-77. PubMed ID: 19404540
[TBL] [Abstract][Full Text] [Related]
16. Potent bivalent thrombin inhibitors: replacement of the scissile peptide bond at P(1)-P(1)' with arginyl ketomethylene isosteres.
Steinmetzer T; Zhu BY; Konishi Y
J Med Chem; 1999 Aug; 42(16):3109-15. PubMed ID: 10447955
[TBL] [Abstract][Full Text] [Related]
17. Detecting Allosteric Networks Using Molecular Dynamics Simulation.
Bowerman S; Wereszczynski J
Methods Enzymol; 2016; 578():429-47. PubMed ID: 27497176
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to thrombin directed against both of its cryptic exosites.
Mollica L; Preston RJ; Chion AC; Lees SJ; Collins P; Lewis S; Lane DA
Br J Haematol; 2006 Feb; 132(4):487-93. PubMed ID: 16412021
[TBL] [Abstract][Full Text] [Related]
19. Impact of protein-protein contacts on the conformation of thrombin-bound hirudin studied by comparison with the nuclear magnetic resonance solution structure of hirudin(1-51).
Szyperski T; Güntert P; Stone SR; Tulinsky A; Bode W; Huber R; Wüthrich K
J Mol Biol; 1992 Dec; 228(4):1206-11. PubMed ID: 1474586
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin.
Liu CC; Brustad E; Liu W; Schultz PG
J Am Chem Soc; 2007 Sep; 129(35):10648-9. PubMed ID: 17685615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
